BR0109517A - métodos e composições sinérgicas para tratar o cáncer - Google Patents

métodos e composições sinérgicas para tratar o cáncer

Info

Publication number
BR0109517A
BR0109517A BRPI0109517-0A BR0109517A BR0109517A BR 0109517 A BR0109517 A BR 0109517A BR 0109517 A BR0109517 A BR 0109517A BR 0109517 A BR0109517 A BR 0109517A
Authority
BR
Brazil
Prior art keywords
cancer
compositions
agents
synergistic
treating cancer
Prior art date
Application number
BRPI0109517-0A
Other languages
English (en)
Inventor
Francis Y Lee
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0109517A publication Critical patent/BR0109517A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"MéTODOS E COMPOSIçõES SINéRGICAS PARA TRATAR O CáNCER". A presente invenção proporciona um método sinérgico para o tratamento de câncer, o qual compreende administrar a uma espécie de mamífero estando necessitada do mesmo uma quantidade sinérgica e terapeuticamente efetiva de: (1) pelo menos um agente selecionado do grupo consistido em agentes citotóxicos e agentes citostáticos, e (2) um composto de fórmula I ou um sal farmaceuticamente aceitável do mesmo. A presente invenção adicionalmente proporciona uma composição farmacêutica para o tratamento sinérgico de câncer, a qual compreende pelo menos um agente selecionado do grupo consistindo em agentes citotóxicos antiproliferativos e agentes citostáticos antiproliferativos, um composto de fórmula I, e um veículo farmaceuticamente aceitável.
BRPI0109517-0A 2000-03-27 2001-03-22 métodos e composições sinérgicas para tratar o cáncer BR0109517A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19227800P 2000-03-27 2000-03-27
PCT/US2001/009193 WO2001072721A2 (en) 2000-03-27 2001-03-22 Synergistic methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
BR0109517A true BR0109517A (pt) 2006-08-29

Family

ID=22709017

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0109517-0A BR0109517A (pt) 2000-03-27 2001-03-22 métodos e composições sinérgicas para tratar o cáncer

Country Status (24)

Country Link
US (1) US6537988B2 (pt)
EP (1) EP1272193B1 (pt)
JP (1) JP5110756B2 (pt)
KR (1) KR20020084254A (pt)
CN (1) CN100384424C (pt)
AR (1) AR028296A1 (pt)
AT (1) ATE430570T1 (pt)
AU (2) AU4768301A (pt)
BR (1) BR0109517A (pt)
CA (1) CA2404712A1 (pt)
CZ (1) CZ20023220A3 (pt)
DE (1) DE60138611D1 (pt)
ES (1) ES2325055T3 (pt)
HU (1) HUP0301690A3 (pt)
IL (1) IL151373A0 (pt)
MX (1) MXPA02009463A (pt)
MY (1) MY127082A (pt)
NO (1) NO20024610L (pt)
PE (1) PE20011291A1 (pt)
RU (1) RU2264217C2 (pt)
TW (1) TWI310684B (pt)
UY (1) UY26635A1 (pt)
WO (1) WO2001072721A2 (pt)
ZA (1) ZA200207766B (pt)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE408612T1 (de) * 1996-11-18 2008-10-15 Biotechnolog Forschung Gmbh Epothilone e und f
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
WO2002028409A2 (en) * 2000-10-05 2002-04-11 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
HUP0303719A2 (hu) * 2000-10-16 2004-03-01 Neopharm, Inc. Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
CA2440555A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
KR20030094415A (ko) * 2001-05-16 2003-12-11 노파르티스 아게 Ν-｛5-[4-(4-메틸-피페라지노-메틸)-벤조일아미도]-2-메틸페닐｝-4-(3-피리딜)-2-피리미딘-아민 및 화학치료제를포함하는 배합물
WO2003035047A2 (en) * 2001-10-25 2003-05-01 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
US7074921B2 (en) * 2001-11-13 2006-07-11 Bristol Myers Squibb Company Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
BR0215184A (pt) * 2001-12-20 2006-06-06 Bristol Myers Squibb Co composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20030147813A1 (en) * 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
WO2003097164A1 (en) * 2002-05-17 2003-11-27 Aventis Pharma S.A. Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
EP2316922B1 (en) * 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
EP2179745A1 (en) * 2002-06-10 2010-04-28 Novartis AG Combinations comprising epothilones and pharmaceutical uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
KR101173510B1 (ko) * 2002-08-23 2012-08-21 슬로안-케테링인스티튜트퍼캔서리서치 에포틸론, 이의 중간물질과 유사체의 합성 및 이들의 용도
US20040209930A1 (en) * 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
JP2006526662A (ja) * 2003-06-05 2006-11-24 アシュカル，チャールズ 過増殖性細胞疾患を治療する方法
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
US7759472B2 (en) * 2003-08-27 2010-07-20 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
WO2005046665A1 (en) * 2003-11-13 2005-05-26 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
US7612071B2 (en) * 2004-03-12 2009-11-03 Syntrix Biosystems, Inc. Compositions and methods employing aminopterin
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
EP1732549A4 (en) * 2004-03-18 2009-11-11 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CA2559221A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050277629A1 (en) * 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
WO2005092384A2 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy with azd2171 and a platinum anti-tumour agent
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
JP4699450B2 (ja) 2004-04-15 2011-06-08 ジェネンコー・インターナショナル・インク Ｃａｂ分子、ｃｅａを対象とするａｄｅｐｔ構築
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
GB0419071D0 (en) 2004-08-26 2004-09-29 Mgx Internat Ltd Display device
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
EP1828249B1 (en) * 2004-12-03 2010-12-29 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
JP4957250B2 (ja) * 2005-01-19 2012-06-20 ゼリア新薬工業株式会社 抗腫瘍剤
CN102886045A (zh) * 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
US20060233810A1 (en) * 2005-04-15 2006-10-19 Yaolin Wang Methods and compositions for treating or preventing cancer
US8101728B2 (en) 2005-04-28 2012-01-24 Danisco Us Inc. TAB molecules
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
US20060286103A1 (en) * 2005-06-15 2006-12-21 Parag Kolhe Stable antibody formulation
FR2887454B1 (fr) * 2005-06-28 2009-06-05 Sanofi Aventis Sa Combinaisons antitumorales contenant des derives du taxane et des sigma ligands
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
CA2642762A1 (en) 2006-02-16 2007-08-30 Schering Corporation Pyrrolidine derivatives as erk inhibitors
WO2007103828A2 (en) * 2006-03-02 2007-09-13 The Board Of Regents Of The University Of Texas System Fluorocytidine derivatives and cox-2 inhibitors for the treatment of cancer
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California POLY THERAPY FOR TREATING CANCER
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
US20080085881A1 (en) * 2006-10-06 2008-04-10 Aimery De Gramont Stop-and-go oxaliplatin treatment regimens
WO2008065409A2 (en) * 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
CA2679919C (en) * 2007-03-02 2015-12-15 University Of Wollongong Compositions and methods for delivery of anti-cancer agents
WO2008115478A2 (en) * 2007-03-19 2008-09-25 University Of Medicine And Dentistry Of New Jersey Method of cancer detection and treatment
ES2526718T3 (es) 2007-09-10 2015-01-14 Curis, Inc. Inhibidores de EGFR basados en sales de tartrato o complejos de quinazolina que contienen un resto que se une al cinc
WO2009033204A1 (en) * 2007-09-12 2009-03-19 University Of Wollongong Multi-component compositions and methods for delivery of anti-cancer agents
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2082745T3 (da) 2007-12-28 2013-03-25 Deutsches Krebsforsch Kræftterapi med en parvovirus kombineret med kemoterapi
PL2236145T3 (pl) * 2008-01-28 2014-08-29 Nanocarrier Co Ltd Kompozycja farmaceutyczna i lek złożony
KR20100117123A (ko) 2008-02-21 2010-11-02 쉐링 코포레이션 Ｅｒｋ 억제제인 화합물
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20110182888A1 (en) * 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
US20090312360A1 (en) * 2008-06-17 2009-12-17 Wyeth Antineoplastic Combinations Containing HKI-272 and Vinorelbine
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
MX2011005096A (es) * 2008-11-13 2011-11-18 Link Medicine Corp Derivados de azaquinolinona y usos de los mismos.
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
EP2370103B1 (en) * 2008-11-28 2016-03-23 Novartis AG Pharmaceutical combinations comprising an isoxazole derived hsp90-inhibitor and the her2 inhibitor trastuzumab
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP3566719A1 (en) 2010-05-18 2019-11-13 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
PL2500036T3 (pl) * 2011-03-18 2014-10-31 Metheresis Translational Res Sa Inhibitory met do zwiększania skuteczności radioterapii
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN103374000B (zh) * 2012-04-13 2015-11-11 中国科学院广州生物医药与健康研究院 嘧啶并二氮杂卓类化合物及其药用组合物和应用
BR112016000546A2 (pt) 2013-07-12 2017-11-21 Ophthotech Corp métodos para tratar ou prevenir condições oftalmológicas
CN107043456B (zh) * 2017-04-19 2019-05-17 川北医学院 对氧环己酮与l-苯丙氨酸氮芥共聚物及其应用
EP3642344A4 (en) 2017-06-21 2021-03-31 The University of North Carolina at Chapel Hill PROCEDURES AND COMPOSITIONS FOR CANCER CELL TARGETING CHIMERIC ANTIGEN RECEPTORS
US11068254B1 (en) 2020-06-10 2021-07-20 Cigna Intellectual Property, Inc. Systems and methods for generating and managing domain-based technology architecture
EP4346800A1 (en) * 2021-06-03 2024-04-10 University of Cincinnati Bzd-1 as a chemosensitizer of cancer
CN113244388A (zh) * 2021-07-01 2021-08-13 江苏先声药业有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
US11879010B2 (en) 2021-09-30 2024-01-23 The Charlotte Mecklenburg Hospital Authority Methods and compositions for pretargeted immunotherapy
CN114712377B (zh) * 2022-04-26 2023-08-15 江苏师范大学 断血流皂苷a在制造药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
DE19706584C2 (de) * 1997-02-21 2002-09-26 Aeg Energietechnik Gmbh Hochtemperaturbrennstoffzellen mit Erwärmung des Reaktionsgases
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
WO1999002573A1 (en) * 1997-07-08 1999-01-21 Union Carbide Chemicals & Plastics Technology Cor Poration Method for reducing sheeting during olefin polymerization
CN1129431C (zh) 1997-12-22 2003-12-03 先灵公司 苯并芳庚并吡啶类化合物与抗肿瘤药联合用于治疗增生性疾病
ID30139A (id) * 1999-01-21 2001-11-08 Bristol Myers Squibb Co Kompleks dari inhibitor ras-farnesiltransferase dan sulfobutileter-7- -siklodekstrin atau 2-hidroksipropil- -siklodekstrin dan metodanya

Also Published As

Publication number Publication date
AU4768301A (en) 2001-10-08
EP1272193A2 (en) 2003-01-08
HUP0301690A2 (hu) 2003-08-28
IL151373A0 (en) 2003-04-10
RU2264217C2 (ru) 2005-11-20
TWI310684B (en) 2009-06-11
PE20011291A1 (es) 2002-01-13
WO2001072721A3 (en) 2002-06-13
RU2002129000A (ru) 2004-03-27
JP2003528864A (ja) 2003-09-30
CN1419452A (zh) 2003-05-21
NO20024610D0 (no) 2002-09-26
US20020002162A1 (en) 2002-01-03
KR20020084254A (ko) 2002-11-04
US6537988B2 (en) 2003-03-25
MXPA02009463A (es) 2003-04-10
ES2325055T3 (es) 2009-08-25
AR028296A1 (es) 2003-04-30
MY127082A (en) 2006-11-30
ATE430570T1 (de) 2009-05-15
DE60138611D1 (de) 2009-06-18
CN100384424C (zh) 2008-04-30
UY26635A1 (es) 2001-10-25
CZ20023220A3 (cs) 2003-11-12
CA2404712A1 (en) 2001-10-04
WO2001072721A2 (en) 2001-10-04
HUP0301690A3 (en) 2005-05-30
ZA200207766B (en) 2003-01-20
AU2001247683B2 (en) 2006-01-12
NO20024610L (no) 2002-11-25
EP1272193B1 (en) 2009-05-06
JP5110756B2 (ja) 2012-12-26

Similar Documents

Publication Publication Date Title
BR0109517A (pt) métodos e composições sinérgicas para tratar o cáncer
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
RS20050522A (en) Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
MY123354A (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
BR9709942A (pt) Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo
DE69940951D1 (de) Nd wachstumshemmende mittel
TW200639159A (en) Treatment of pain
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
BG105600A (en) 13-membered azalides and their use as antibiotic agents
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
CR20230052A (es) Combinaciones para el tratamiento de cáncer.
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
BR9813317A (pt) Composto, composição farmacêutica para tratar infecções bacterianas, e, processos para tratar infecções bacterianas, e para preparar um composto
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
BR9908125A (pt) Composto, composto dimérico, composição farmacêutica, uso do composto, processo compreendendo inibir células de câncer, e, processo terapêutico
ATE485818T1 (de) Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
RU2007143434A (ru) 4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний
EA200400348A1 (ru) Цисплатиновые составы пониженной токсичности и способы их применения
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]